PR Yu: Stephen Towe, CEO of Leo Cancer Care, shared the exciting news of receiving 510k approval from the FDA
PR Yu, Founder and Managing Partner of Yu Galaxy, shared on LinkedIn:
“I was elated when Stephen Towe, CEO of our portfolio company Leo Cancer Care, shared the exciting news of receiving the groundbreaking 510k approval from the FDA. This achievement marks a significant milestone that the entire team has tirelessly pursued for years, working day and night.
For Stephen, this milestone holds even deeper significance, tracing back to his college days when he tragically lost his father to cancer. Since then, the goal of developing better cures for cancer has been a driving force, propelling him forward with unwavering determination.
With this FDA approval, millions of cancer patients worldwide will now have access to upright radiotherapy, a revolutionary approach pioneered by Leo Cancer Care, which promises to be more effective, efficient, and compassionate.
As an investor deeply committed to creating positive change, I find pure joy in directing resources towards visionary teams like Leo Cancer Care, who are dedicated to improving our world.
Meeting the passionate individuals and their families at Leo Cancer Care, both in the UK and the US, filled me with happiness. And the knowledge that our collective efforts will result in countless lives being saved brings me profound satisfaction.”
Read further.
Source: PR Yu/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023